Gastric bypass is preferable to sleeve gastrectomy (less reflux) and can fully treat type 2 diabetes; for patients who fail dieting, bypass rather than sleeve should be chosen (2021 statement).
Original statement
ويجي يقولي أنا عايز أعمل عملية تحويل المسار بدون نقاش التكميم عملية سيئة ومشاكلها كثيرة
verbatim according to source. Translation by the project; the Arabic wording is authoritative.
Translation
Gastric bypass is preferable to sleeve gastrectomy (less reflux) and can fully treat type 2 diabetes; for patients who fail dieting, bypass rather than sleeve should be chosen (2021 statement).
Origin
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- عمليات السمنة ايه افضل عملية لصحتك وبدون خطورة (Open source)
- Published
- 31 March 2021
- Timestamp
- 0:02:26 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); wording may contain transcription errors; no timestamps available. Embedded time marker approx. [02:25] in archive transcript.
- Claimed mechanism
Bypass diverts carbohydrate load away from pancreas/liver.
- Claimed health effect
Diabetes cure; less reflux.
- Population concerned
Patients who failed diet
- Geographic restriction by Elawady
none found
Scientific assessment
Mostly true – Correct at its core, but with limitations or minor inaccuracies.
Certainty of evidence: moderate – Further research may still affect the assessment.
1. What was claimed?
Bypass better than sleeve; bypass can fully cure T2D.
2. What is demonstrably correct?
Reflux: bypass superior (SLEEVEPASS esophagitis 7% vs 31%; SM-BOSS reflux remission 60.4% vs 25.0%; STAMPEDE, A-BAR-24: GERD reported in 10% after bypass vs 27% after sleeve at 5 years). Weight loss modestly greater after bypass (SLEEVEPASS +8.4 %EWL).
3. What is wrong or exaggerated?
'Can treat diabetes completely' is overstated: diabetes remission after bypass declines (Adams 51% at 12 years; Mingrone RYGB 25% at 10 years) and SLEEVEPASS/STAMPEDE show no significant remission difference between bypass and sleeve. In STAMPEDE only 22.4% of bypass patients reached HbA1c <=6.0% without diabetes medication at 5 years (A-BAR-24; trial not powered for bypass vs sleeve). Bypass carries specific harms (A-BAR-10, A-BAR-11, A-BAR-14, I-BAR-08).
4. What remains unclear?
Individual choice depends on reflux, BMI, diabetes and patient factors.
5. Which studies support it?
6. Which studies contradict it?
A-BAR-04, I-BAR-03, A-BAR-24, A-BAR-14, I-BAR-08.
7. What applies to Germany and Europe?
Most key data are European (Sweden SOS/SOReg, Finland SLEEVEPASS, Switzerland SM-BOSS). European and international society guidelines consider bariatric surgery for severe obesity with lifelong follow-up.
8. What is known about Egypt?
No Egypt-specific outcome data were identified in this review. Elawady states in a transcript that sleeve gastrectomy is very widely performed in Egypt ('مصر كلها بتعملها'); the procedure-specific risks (reflux, deficiencies) apply wherever it is performed, and follow-up quality (supplements, endoscopy, mental-health screening) determines part of the risk.
9. What practical conclusion is appropriate?
Procedure choice should be individual; bypass is commonly preferred when reflux exists.
Assessment details
- Rationale for certainty of evidence
Two RCTs show less reflux after bypass; diabetes 'complete cure' is overstated.
- Source quality
Short 2021 video; position differs from his later statements opposing all bariatric operations (2025: 'against any operation', 'sleeve is a crime'). Both positions are recorded; no motive is implied.
- Regional transferability
European RCTs.
- Individual exceptions
Bypass has its own risks (alcohol use disorder, bone loss, internal hernia, marginal ulcer).
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 25 October 2026 provisional
In plain language
In a 2021 video Elawady said that sleeve gastrectomy is a bad operation because of reflux and that patients who cannot lose weight with diet should choose a gastric bypass, which can 'completely' treat diabetes. The reflux part matches randomized trials. The idea of a complete cure of diabetes is too optimistic, because diabetes returns in many patients over the years. In later videos (2025) he opposed all such operations.
Studies on this claim
Studies supporting the claim (2)
-
Finnish trial: sleeve vs bypass after 10 years
Salminen P et al.. JAMA Surg 2022 · PMID 35731535 · DOI 10.1001/jamasurg.2022.2229Randomised controlled trialcited by the Tayebat archiveabstract only checked★ key studyEsophagitis was found in 31% after sleeve vs 7% after bypass; Barrett's esophagus was 4% in both groups.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare sleeve vs bypass
- How was the study done?
RCT with 10-year follow-up
- How many people, animals or samples were studied?
240 patients
- What was actually found?
More esophagitis after sleeve; Barrett's equal
- How large was the observed effect?
31% vs 7%; BE 4% vs 4%
- What do the results mean in everyday life?
Sleeve often causes reflux damage; bypass less so
- What are the study's limitations?
Attrition; small
- What does it say about Elawady's specific claim?
Supports reflux claim, not sleeve-specific Barrett's
- Do the results apply to Germany and Europe?
Directly European
- What can explicitly not be concluded from this study?
Cancer risk
-
Swiss trial: sleeve vs bypass
Peterli R et al.. JAMA 2018 · PMID 29340679 · DOI 10.1001/jama.2017.20897Randomised controlled trialindependent cross-checkabstract only checked★ key studyReflux got worse in about 32% after sleeve vs 6% after bypass.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare procedures
- How was the study done?
RCT
- How many people, animals or samples were studied?
217
- What was actually found?
More reflux after sleeve
- How large was the observed effect?
31.8% vs 6.3%
- What do the results mean in everyday life?
Reflux is common but not universal
- What are the study's limitations?
Exploratory reflux outcome
- What does it say about Elawady's specific claim?
Supports increase, refutes 'inevitable'
- Do the results apply to Germany and Europe?
European
- What can explicitly not be concluded from this study?
Long-term BE
No study in this group is marked as key.
Studies contradicting or limiting the claim (6)
-
12 years after gastric bypass
Adams TD et al.. N Engl J Med 2017 · PMID 28930514 · DOI 10.1056/NEJMoa1700459Cohort studycited by the Tayebat archivefull text checked★ key studyHalf of the patients with diabetes were still in remission after 12 years; new diabetes was about 90% less frequent than in non-operated people.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Long-term outcomes
- How was the study done?
Prospective controlled cohort
- How many people, animals or samples were studied?
1156 adults
- What was actually found?
Remission declines but benefit persists
- How large was the observed effect?
Remission 51% at 12 y; incident T2D OR 0.08
- What do the results mean in everyday life?
Relapse happens, but many stay in remission
- What are the study's limitations?
Non-randomized; small diabetic subgroup; many controls later had surgery; mostly women in Utah
- What does it say about Elawady's specific claim?
Relapse claim true; 'benefit erodes away' overstated
- Do the results apply to Germany and Europe?
Applicable
- What can explicitly not be concluded from this study?
Exact causal effect; outcomes for sleeve gastrectomy
-
Italian 10-year diabetes surgery trial
Mingrone G et al.. Lancet 2021 · PMID 33485454 · DOI 10.1016/S0140-6736(20)32649-0Randomised controlled trialindependent cross-checkabstract only checked★ key studyMore than half of those in remission at 2 years relapsed, but their sugar control stayed good (HbA1c 6.7%) and complications were fewer than with medicines alone.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Durability
- How was the study done?
RCT
- How many people, animals or samples were studied?
60
- What was actually found?
Relapse frequent; control better
- How large was the observed effect?
RR complications 0.07
- What do the results mean in everyday life?
Relapse does not mean the benefit is lost
- What are the study's limitations?
Tiny
- What does it say about Elawady's specific claim?
Partly supports
- Do the results apply to Germany and Europe?
European
- What can explicitly not be concluded from this study?
Generalizability
-
Alcohol and drugs after surgery
King WC et al.. Surg Obes Relat Dis 2017 · PMID 28528115 · DOI 10.1016/j.soard.2017.03.021Cohort studycited by the Tayebat archivefull text checkedOne in five bypass patients reported new alcohol problem symptoms within 5 years.
Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
SUD
- How was the study done?
Cohort
- How many people, animals or samples were studied?
2003
- What was actually found?
Higher after RYGB
- How large was the observed effect?
AHR 2.08
- What do the results mean in everyday life?
Alcohol risk is real, mainly after bypass
- What are the study's limitations?
No non-surgical control; self-reported screening symptoms; 22-34% missing at each follow-up; sleeve not studied
- What does it say about Elawady's specific claim?
Supports
- Do the results apply to Germany and Europe?
Applicable
- What can explicitly not be concluded from this study?
Sleeve-specific risk
-
Swedish study: fractures after gastric bypass
Axelsson KF et al.. J Bone Miner Res 2018 · PMID 30011091 · DOI 10.1002/jbmr.3553Cohort studyindependent cross-checkabstract only checkedFracture risk was about 26-32% higher than in similar people without surgery.
Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Fracture
- How was the study done?
Matched cohort
- How many people, animals or samples were studied?
~78,000
- What was actually found?
Higher risk
- How large was the observed effect?
HR 1.26-1.32
- What do the results mean in everyday life?
Bone protection is important after bypass
- What are the study's limitations?
Short follow-up
- What does it say about Elawady's specific claim?
Supports (bypass)
- Do the results apply to Germany and Europe?
European
- What can explicitly not be concluded from this study?
Sleeve risk
-
Bowel obstruction after gastric bypass
Elms L et al.. Surg Endosc 2014 · PMID 24380988 · DOI 10.1007/s00464-013-3361-1Case series / case reportcited by the Tayebat archiveabstract only checkedAbout 4 in 100 patients needed another operation for possible bowel obstruction.
Does the study support the specific claim? Unclear · Methodological quality: low · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Complication causes
- How was the study done?
Retrospective review
- How many people, animals or samples were studied?
2395
- What was actually found?
3.9% reoperation
- How large was the observed effect?
3.9%
- What do the results mean in everyday life?
Late complications occur
- What are the study's limitations?
Single centre
- What does it say about Elawady's specific claim?
General harm, not sleeve-specific
- Do the results apply to Germany and Europe?
Applicable
- What can explicitly not be concluded from this study?
Comparison with non-surgery
-
Ulcers after gastric bypass
Sverdén E et al.. Ann Surg 2016 · PMID 26106845 · DOI 10.1097/SLA.0000000000001300Cohort studycited by the Tayebat archiveabstract only checkedDiabetes and earlier ulcers increased the risk of ulcers at the new stomach connection.
Does the study support the specific claim? Unclear · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Risk factors
- How was the study done?
Registry cohort
- How many people, animals or samples were studied?
20,294
- What was actually found?
See results
- How large was the observed effect?
HR 1.26-2.70
- What do the results mean in everyday life?
Ulcers are a known complication
- What are the study's limitations?
Registry coding
- What does it say about Elawady's specific claim?
Indirect
- Do the results apply to Germany and Europe?
European
- What can explicitly not be concluded from this study?
Incidence vs non-surgery
No study in this group is marked as key.
Studies with mixed or unclear results (1)
-
STAMPEDE: surgery vs medicines for diabetes
Schauer PR et al.. N Engl J Med 2017 · PMID 28199805 · DOI 10.1056/NEJMoa1600869Randomised controlled trialcited by the Tayebat archivefull text checkedAfter 5 years, 23-29% of operated patients reached near-normal HbA1c vs 5% with medicines alone.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Diabetes RCT
- How was the study done?
RCT
- How many people, animals or samples were studied?
150
- What was actually found?
Surgery better
- How large was the observed effect?
29%/23% vs 5%
- What do the results mean in everyday life?
Surgery helps more, but most did not reach the target and only 15-22% reached it without diabetes medicines
- What are the study's limitations?
Small single-centre trial; not blinded; more drop-outs in the medical group; ITT result not significant
- What does it say about Elawady's specific claim?
Contradicts 'benefit erodes away'
- Do the results apply to Germany and Europe?
Applicable
- What can explicitly not be concluded from this study?
Hard outcomes
No study in this group is marked as key.
Regional context
Germany / EU
Most key data are European (Sweden SOS/SOReg, Finland SLEEVEPASS, Switzerland SM-BOSS). European and international society guidelines consider bariatric surgery for severe obesity with lifelong follow-up.
Egypt
No Egypt-specific outcome data were identified in this review. Elawady states in a transcript that sleeve gastrectomy is very widely performed in Egypt ('مصر كلها بتعملها'); the procedure-specific risks (reflux, deficiencies) apply wherever it is performed, and follow-up quality (supplements, endoscopy, mental-health screening) determines part of the risk.
What applies in my country?
General scientific assessment
Mostly true Reflux comparison correct; 'complete diabetes cure' overstated.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Effect of Laparoscopic Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass on Weight Loss, Comorbidities, and Reflux at 10 Years in Adult Patients With Obesity: The SLEEVEPASS Randomized Clinical Trial.. Salminen P et al.. JAMA Surg 2022 · PMID 35731535 · DOI 10.1001/jamasurg.2022.2229
- Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity: The SM-BOSS Randomized Clinical Trial.. Peterli R et al.. JAMA 2018 · PMID 29340679 · DOI 10.1001/jama.2017.20897
- Weight and Metabolic Outcomes 12 Years after Gastric Bypass.. Adams TD et al.. N Engl J Med 2017 · PMID 28930514 · DOI 10.1056/NEJMoa1700459
- Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial.. Mingrone G et al.. Lancet 2021 · PMID 33485454 · DOI 10.1016/S0140-6736(20)32649-0
- Alcohol and other substance use after bariatric surgery: prospective evidence from a U.S. multicenter cohort study.. King WC et al.. Surg Obes Relat Dis 2017 · PMID 28528115 · DOI 10.1016/j.soard.2017.03.021
- Fracture Risk After Gastric Bypass Surgery: A Retrospective Cohort Study.. Axelsson KF et al.. J Bone Miner Res 2018 · PMID 30011091 · DOI 10.1002/jbmr.3553
- Causes of small bowel obstruction after Roux-en-Y gastric bypass: a review of 2,395 cases at a single institution.. Elms L et al.. Surg Endosc 2014 · PMID 24380988 · DOI 10.1007/s00464-013-3361-1
- Risk Factors for Marginal Ulcer After Gastric Bypass Surgery for Obesity: A Population-based Cohort Study.. Sverdén E et al.. Ann Surg 2016 · PMID 26106845 · DOI 10.1097/SLA.0000000000001300
- Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes.. Schauer PR et al.. N Engl J Med 2017 · PMID 28199805 · DOI 10.1056/NEJMoa1600869